Literature DB >> 8205433

Non-radical therapy for early gastric cancer.

J P Heesakkers1, D J Gouma, F B Thunnissen, M H Bemelmans, M F Von Meyenfeldt.   

Abstract

To assess the potential benefit of R2 gastrectomy for patients with early gastric cancer, complications and long-term survival of patients who underwent conventional resection with limited lymphadenectomy (R1 gastrectomy) were analysed retrospectively. Resection margins of all 46 consecutive patients were free from tumour. Tumours were limited to the mucosa in 35 patients and infiltrated the submucosa in 11. Positive lymph nodes were found in two patients. The 30-day mortality was two patients, and cardiac and pulmonary complications occurred in five and six respectively. Anastomotic leakage developed in two patients. During 5 years of follow-up two patients died from tumour recurrence; one of these had lymph node metastases at the initial resection. Resection with limited lymphadenectomy for early gastric cancer results in a 91 per cent 5-year survival rate without the need for R2 gastrectomy with its probably higher morbidity and mortality.

Entities:  

Mesh:

Year:  1994        PMID: 8205433     DOI: 10.1002/bjs.1800810422

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  4 in total

Review 1.  Early gastric cancer in Europe.

Authors:  S M Everett; A T Axon
Journal:  Gut       Date:  1997-08       Impact factor: 23.059

2.  Survival after surgical treatment of early gastric cancer: surgical techniques and long-term survival.

Authors:  Shiro Kikuchi; Natsuya Katada; Shinichi Sakuramoto; Nobuyuki Kobayashi; Hitoshi Shimao; Masahiko Watanabe; Yoshiki Hiki
Journal:  Langenbecks Arch Surg       Date:  2004-02-18       Impact factor: 3.445

3.  Superficial spreading type of early gastric cancer.

Authors:  K Kitamura; T Yamaguchi; K Okamoto; T Nishida; T Takahashi
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

4.  Rationale for extensive lymphadenectomy in early gastric carcinoma.

Authors:  K Miwa; I Miyazaki; H Sahara; T Fujimura; Y Yonemura; M Noguchi; R Falla
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.